PTPN11 and cancer: Intriguingly, while SHP2-AIs are structurally related, share the same binding mode, and have comparable biochemical and cellular potencies, they exhibit a wide range of efficacies in cancers driven by aberrant RAS-MAPK activation (12, 22–25, 27, 28, 30–35).